Article
Synthetic vaccines and HIV-1 hypervariability: a "mixotope" approach.
Peptide research - 1 Jan 2000
Gras-Masse H, Ameisen J C, Boutillon C, Rouaix F, Bossus M, Deprez B, Neyrinck J L, Capron A, Tartar A
Abstract excerpt
The hypervariability of the gp120 envelope protein principal neutralizing domain, the V3 loop, represents a major problem in the design of vaccines against HIV-1. We have designed a mixed V3 loop peptide, termed "mixotope," obtained in a unique synthesis, and containing around 7.5 x 10(5) different sequences of 22 to 25 residues, organized around the conserved GPGR tetrapeptide. Free or coupled to a carrier...
Topics
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Amino Acid Sequence
- Amino Acids
- Animals
- Female
- Genetic Variation
- HIV-1
- Hydrolysis
- Immunization
- Molecular Sequence Data